Novel Therapies for Metastatic Castrate Resistant Prostate Cancer with PARP-Inhibitors and BITE Immunotherapy – Enduring Webcast

Description

Program Description

---

There is an unmet need to develop novel therapies beyond targeting AR signaling for mCRPC. Poly (ADP-ribose) polymerase inhibitors (PARPi) belong to a class of targeted agents being designed for the treatment of homologous recombination repair (HRR) deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in early phase trials as monotherapy for HRR-deficient mCRPC. Among them, olaparib and rucaparib have breakthrough designations for BRCA1/2-mutated mCRPC. PSMA bispecific T-cell engager (BiTE®) immune therapy mediating T-cell killing of tumor cells plays an important role in patients with mCRPC. As a BiTE immune therapy, pasotuxizumab is designed to engage a patient’s own T cells to PSMA expressing cells. The rationale behind the clinical trials that led to PARP

Intended Audience

---

This webcast is designed to meet the educational needs of hematologists/oncologists, urologists, nurse practitioners, physician assistants, and nurses involved in the care and treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC).

Commercial Supporter

---

This activity is supported by an educational grant from Amgen, Inc.